[HTML][HTML] In silico drug combination discovery for personalized cancer therapy

M Jeon, S Kim, S Park, H Lee, J Kang - BMC systems biology, 2018 - Springer
Background Drug combination therapy, which is considered as an alternative to single drug
therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug …

[HTML][HTML] In silico drug combination discovery for personalized cancer therapy

M Jeon, S Kim, S Park, H Lee, J Kang - BMC Systems Biology, 2018 - ncbi.nlm.nih.gov
Background Drug combination therapy, which is considered as an alternative to single drug
therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug …

In silico drug combination discovery for personalized cancer therapy.

M Jeon, S Kim, S Park, H Lee… - BMC Systems Biology, 2018 - search.ebscohost.com
Background: Drug combination therapy, which is considered as an alternative to single drug
therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug …

In silico drug combination discovery for personalized cancer therapy

M Jeon, S Kim, S Park, H Lee, J Kang - BMC Systems Biology, 2018 - go.gale.com
Background Drug combination therapy, which is considered as an alternative to single drug
therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug …

In silico drug combination discovery for personalized cancer therapy

M Jeon, S Kim, S Park, H Lee… - BMC systems …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Drug combination therapy, which is considered as an alternative to single drug
therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug …

In silico drug combination discovery for personalized cancer therapy.

M Jeon, S Kim, S Park, H Lee, J Kang - BMC Systems Biology, 2018 - europepmc.org
BACKGROUND: Drug combination therapy, which is considered as an alternative to single
drug therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As …

[HTML][HTML] In silico drug combination discovery for personalized cancer therapy

M Jeon, S Kim, S Park, H Lee… - BMC Systems …, 2018 - bmcsystbiol.biomedcentral.com
Drug combination therapy, which is considered as an alternative to single drug therapy, can
potentially reduce resistance and toxicity, and have synergistic efficacy. As drug combination …

In silico drug combination discovery for personalized cancer therapy

M Jeon, S Kim, S Park, H Lee, J Kang - BMC Systems Biology, 2018 - pure.korea.ac.kr
Background: Drug combination therapy, which is considered as an alternative to single drug
therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug …

[PDF][PDF] In silico drug combination discovery for personalized cancer therapy

M Jeon, S Kim, S Park, H Lee, J Kang - 2018 - academia.edu
Background: Drug combination therapy, which is considered as an alternative to single drug
therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug …

[PDF][PDF] In silico drug combination discovery for personalized cancer therapy

M Jeon, S Kim, S Park, H Lee, J Kang - 2018 - bmcsystbiol.biomedcentral.com
Background: Drug combination therapy, which is considered as an alternative to single drug
therapy, can potentially reduce resistance and toxicity, and have synergistic efficacy. As drug …